• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sage Therapeutics wins priority review for intravenous postpartum depression drug

May 30, 2018 By Sarah Faulkner

Sage TherapeuticsSage Therapeutics (NSDQ:SAGE) said today that the FDA accepted its new drug application for an intravenous formulation of brexanolone as a treatment for postpartum depression.

The application was accepted under priority review status, according to the Cambridge, Mass.-based company. If approved, the drug would be the first therapy specifically indicated to treat postpartum depression – the most common medical complication of childbirth.

The company’s drug is an allosteric modulator of synaptic and extrasynaptic GABA-A receptors. As an allosteric modulator, it works to indirectly regulate the activity of neurotransmitter receptors, rather than simply turning them on or off.

Sage’s NDA included data from two Phase III trials that evaluated the safety and efficacy of brexanolone in women ages 18 to 45 with moderate and severe postpartum depression. At all doses in both trials, brexanolone demonstrated a significant mean reduction from baseline in the Hamilton Rating Scale for Depression score after 60 hours compared to placebo. The most common adverse events across all treatment groups were headache, dizziness and somnolence, according to Sage.

Because Sage’s drug is a new molecular entity with a new mechanism of action, the FDA plans to hold an advisory committee meeting to discuss the company’s application. The regulatory agency is slated to make a decision regarding Sage’s NDA by December 19.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: sagetherapeutics

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS